Open AccessPCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer
Author(s) -
Wang Tongxin,
Yao Weilei,
Shao Yafei,
Zheng Ruilong,
Huang Feiruo
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13877
Subject(s) - pcaf , cancer , cancer research , pathological , liver cancer , disease , biology , histone , medicine , pathology , gene , genetics
The P300/ CBP ‐associating factor ( PCAF ), a histone acetyltransferase, is involved in metabolic and pathogenic diseases, particularly of the liver. The effects of PCAF on fine‐tuning liver diseases are extremely complex and vary according to different pathological conditions. This enzyme has dichotomous functions, depending on differently modified sites, which regulate the activities of various enzymes, metabolic functions, and gene expression. Here, we summarize the most recent findings on the functions and targets of PCAF in various metabolic and immunological processes in the liver and review these new discoveries and models of PCAF biology in three areas: hepatic metabolic syndrome, inflammatory disease, and cancer. Finally, we discuss the potential implications of these findings for therapeutic interventions in liver diseases.